logo
NIPGR's gene-edited japonica rice shows increased phosphate uptake, 20% more yield

NIPGR's gene-edited japonica rice shows increased phosphate uptake, 20% more yield

The Hindua day ago
Scientists at the Delhi-based National Institute of Plant Genome Research (NIPGR) have used CRISPR-Cas9 gene editing technology to increase phosphate uptake and transport in japonica rice varieties. The resulting rice lines had higher seed and panicle numbers, thereby increasing the yield without compromising seed quality. The studies were carried out in a greenhouse.
Phosphorus is an essential mineral for plant growth and development of plants. In case of limited phosphorus availability, crop productivity drops drastically. Even when phosphate fertilizers are used, only about 15-20% are taken up by plants while the balance gets leached out or lost through runoff.
When the recommended amount of phosphate fertilizer was used, yield increased by 20% in gene edited rice lines. However, when only 10% of the recommended dose of phosphate fertilizer was used, yield in gene-edited rice lines increased by 40% compared with the control, says Dr. Jitender Giri from NIPGR, and the corresponding author of a paper published in Plant Biotechnology Journal.
'The purpose was to just demonstrate that even under extreme conditions of using only 10% of the recommended dose, the gene-edited lines showed increased phosphate uptake resulting in 40% higher yield compared with the control group, where the yield reduced sharply,' says Dr. Giri. 'But if phosphate fertilizer supply is reduced by 10% or even 30%, it is very likely that the gene-edited lines will still outperform the control plants.'
Rice absorbs phosphate through its roots and transfers it to the shoots. One class of transporters brings phosphate from the soil into the root, while another inorganic phosphate transporter (OsPHO1;2) transfers phosphate from the root to the shoot. The NIPGR researchers restricted their work to the phosphate transporter that transfers phosphate from the root to the shoot. 'When the phosphate transporter OsPHO1;2 starts working more, it will create more demand for phosphate in the root. When this happens, the root-bound transporters will bring more phosphate from soil into the root,' he explains. 'We already know there is a negative regulator that controls the expression of the phosphate transporter in the model plant Arabidopsis. But what's happening in rice was not known till now.'
Identification, removal of the repressor
Through in silico and DNA-protein interaction studies, NIPGR researchers identified the repressor (OsWRKY6) and demonstrated that the repressor physically binds to the promoter. To verify if the repressor was indeed reducing the expression of the phosphate transporter, they silenced the repressor by knocking it out by using the CRISPR-Cas9 gene editing tool. When the repressor was knocked out, the expression of the phosphate transporter (OsPHO1;2) increased significantly.
The increased expression of the transporter should have ideally led to more yield. But instead, the gene-edited rice lines fared poorly compared with the control. 'This was unexpected. We figured out that the repressor was also needed for other functions in the plant. While knocking out the repressor gene completely helped in removing the repression of the phosphate transporter thereby increasing the levels of phosphate in the shoot, we were also removing some essential functions regulated by the repressor,' Dr. Giri explains.
Removing the binding site
The researchers then identified the site where the repressor actually binds to the promoter. The binding site in the promoter is a very short sequence of just 30 base pairs. Again CRISPR-Cas9 was used to remove the binding side of the repressor on the promoter. 'We removed only the binding site and not the repressor itself. So the repressor is present in the plant and continues to execute other vital plant functions,' Dr. Giri explains.
The phosphate transporter (OsPHO1;2) is also regulated by other regulators. By specifically removing only the site where the repressor binds to the promoter, the researchers ensured that the binding sites of other regulators are intact so they can continue to bind to the promoter and regulate its function. Dr. Giri likens it to undertaking a very precise, minimal invasive surgery in the promoter gene.
There was enhanced expression of the promoter in the roots, along with increased shoot phosphate accumulation and improved plant growth the gene-edited rice plants leading to increased transfer of phosphate from the root to shoot, when the binding site of the repressor gene was removed from the phosphate promoter.
Though only the binding site in the promoter found in the shoot was gene-edited, the researchers found that other transporters present in the root surface brought more phosphorus into the root. 'The roots start behaving like a sink by absorbing more phosphate from the soil, and this phosphate is distributed throughout the plant,' he says. The team found that the gene-edited lines were channelising the extra phosphate absorbed by the roots to produce more seeds by increasing the number of panicles — the fruiting body which bears seeds — leading to an increase in yield by 20%. The researchers analysed the seed size, seed dimension, seed length, starch and phosphate content, and found the seed dimension or seed quality to be normal.
Since the roots of gene-edited plants absorb more phosphate than before, will it become even more necessary to continue using the same amount of phosphate fertilizer? That only about 20% of the phosphate fertilizer applied is taken up by plants because Dr. Giri says that phosphate is very reactive. In alkaline soil, phosphate forms complexes with either calcium or magnesium, and if it is acidic, it forms complexes with iron and aluminium. Since phosphate complexes are insoluble in nature, the transporters found in the root cannot absorb them. 'In the case of gene-edited rice, the plants will quickly absorb more phosphate before it combines with aluminium, iron, calcium or magnesium and become insoluble,' he explains.
Testing the hypothesis using japonica
For the study, japonica cultivar Nipponbare was used since making gene-edited lines and transgenics is generally easy with japonica. 'Japonica variety is easy to work with; it's not easy to raise transgenics using indica varieties. It will take more time to generate a sufficient number of gene plants when using Indian cultivars,' Dr. Giri says. 'So, we test our hypothesis in the japonica variety because it can be done quickly and more reliably, and then replicate it in Indian indica varieties.'
'It's a very important scientific advancement,' says Dr. P.V. Shivaprasad of the Epigenetics lab in the National Centre for Biological Sciences (NCBS), Bengaluru, who is not part of the study. 'Soil in several parts of India has phosphorus deficiency. When the same modifications are performed in indica rice lines, it will be extremely useful. One must also check the efficacy of phosphate absorption, and how much less phosphate fertilizer can be used without compromising yield in indica lines. Exciting times ahead.'
Off-target events
Activists have raised objections to gene-edited technology on the grounds that the IPRs are held by foreign entities. Dr. Giri says that India is negotiating for a license of the CRISPR-Cas9 technology. CRISPR-Cas9 gene editing technology does not always target only the bases/genes of interest. Off-target events do happen, which is another objection raised by activists.
To address the off-target events problem, Dr. Giri says there are software that predict where an intended gene editing might cause unexpected, unwanted, or even adverse alterations to the genome. 'We checked for all off-target genes to check if there are any changes. In our case, we tested the top 10 contender off-target sites and did not find any deletion on those sites,' Dr. Giri says. Before the seeds are actually approved and released, and farmers are allowed to cultivate, efforts will be taken to ensure that the deletion is restricted only to the receptor binding site on the promoter with no off-target effect actually seen, he says. 'What we do actually is that we produce a large number of lines and then select the best line and check for off-targets,' Dr. Giri says.
'It is very much possible to eliminate off-target events,' says Dr. Shivaprasad. 'There are multiple tools available for guide RNA design that almost eliminate the possibility of off-target events. It is also important to check for off-target regions to ensure that off-target events have not happened. It needs expertise.'
According to Dr. Shivaprasad, there are more than three good in silico tools available to check for off-target events. 'Southern blot analysis, particularly junction fragment analysis, is carried out to verify the successful integration or modification of DNA sequences within a genome and to confirm if multiple copies or half copies are not present,' he says.
NIPGR researchers have used tissue culture-based transgenic generation. When plants are produced using tissue culture, even before seeds are produced the plants are tested to check if gene editing has been precise without any off-target events. 'Only if the gene editing has been precise with no off-target events will we even allow the plants to grow to the seed stage. The rest are discarded. So whatever plant we grow till the seed stage will always carry the correct gene editing. The seeds coming from that plant and from the progeny will carry the phosphate transporter that has been precisely gene-edited to remove the 30 base pairs that form the binding site for the repressor (OsWRKY6),' Dr. Giri says.
Foreign DNA
The third major objection is the presence of foreign DNA. The Cas9 protein used in CRISPR gene editing is derived from Streptococcus pyogenes bacteria. Therefore, Cas9, which acts as a DNA-cutting enzyme, carries foreign DNA. Foreign DNA also comes from soil bacterium that is used as a vector for delivering the CRISPR-Cas9 components into plant cells.
Dr. Giri claims that the DNA from bacteria is removed in the second generation through a simple Mendelian segregation method, as the plants are tested before growing to the seed stage to know if the gene editing has been precise without any off-target events. 'If you have one trait, the next generation will segregate into 3:1, where three will have the foreign DNA, and one will not. In the next generation, foreign DNA free plants are identified and propagated,' he says.
'It is possible to remove the DNA of Agrobacterium tumefaciens — the soil bacterium that is used as a vector for delivering the CRISPR-Cas9 components into plant cells — through the Mendelian segregation method,' confirms Dr. Shivaprasad. When the soil bacterium vector is removed, the S. pyogenes bacterium also gets removed automatically.
India is almost entirely dependent on imports — nearly 4.5 million tonnes of Diammonium phosphate (DAP) — to meet the demand for phosphate fertilizers. The gene-edited technology, if successfully replicated in Indian rice varieties, can possibly contribute towards sustainable agriculture.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Lord of the Rings' director backs long shot de-extinction plan, starring New Zealand's lost moa
'Lord of the Rings' director backs long shot de-extinction plan, starring New Zealand's lost moa

First Post

time2 hours ago

  • First Post

'Lord of the Rings' director backs long shot de-extinction plan, starring New Zealand's lost moa

In New Zealand, it's legal to buy and sell moa bones found on private lands, but not on public conservation areas – nor to export them. read more Filmmaker Peter Jackson owns one of the largest private collections of bones of an extinct New Zealand bird called the moa. His fascination with the flightless ostrich-like bird has led to an unusual partnership with a biotech company known for its grand and controversial plans to bring back lost species. On Tuesday, Colossal Biosciences announced an effort to genetically engineer living birds to resemble the extinct South Island giant moa – which once stood 12 feet (3.6 meters) tall – with $15 million in funding from Jackson and his partner Fran Walsh. The collaboration also includes the New Zealand-based Ngāi Tahu Research Centre. STORY CONTINUES BELOW THIS AD 'The movies are my day job, and the moa are my fun thing I do,' said Jackson. 'Every New Zealand schoolchild has a fascination with the moa.' Outside scientists say the idea of bringing back extinct species onto the modern landscape is likely impossible, although it may be feasible to tweak the genes of living animals to have similar physical traits. Scientists have mixed feelings on whether that will be helpful, and some worry that focusing on lost creatures could distract from protecting species that still exist. The moa had roamed New Zealand for 4,000 years until they became extinct around 600 years ago, mainly because of overhunting. A large skeleton brought to England in the 19th century, now on display at the Yorkshire Museum, prompted international interest in the long-necked bird. Unlike Colossal's work with dire wolves, the moa project is in very early stages. It started with a phone call about two years ago after Jackson heard about the company's efforts to 'de-extinct' – or create genetically similar animals to – species like the woolly mammoth and the dire wolf. Then Jackson put Colossal in touch with experts he'd met through his own moa bone-collecting. At that point, he'd amassed between 300 and 400 bones, he said. STORY CONTINUES BELOW THIS AD In New Zealand, it's legal to buy and sell moa bones found on private lands, but not on public conservation areas – nor to export them. The first stage of the moa project will be to identify well-preserved bones from which it may be possible to extract DNA, said Colossal's chief scientist Beth Shapiro. Those DNA sequences will be compared to genomes of living bird species, including the ground-dwelling tinamou and emu, 'to figure out what it is that made the moa unique compared to other birds,' she said. Colossal used a similar process of comparing ancient DNA of extinct dire wolves to determine the genetic differences with gray wolves. Then scientists took blood cells from a living gray wolf and used CRISPR to genetically modify them in 20 different sites. Pups with long white hair and muscular jaws were born late last year. Working with birds presents different challenges, said Shapiro. Unlike mammals, bird embryos develop inside eggs, so the process of transferring an embryo to a surrogate will not look like mammalian IVF. 'There's lots of different scientific hurdles that need to be overcome with any species that we pick as a candidate for de-extinction,' said Shapiro. 'We are in the very early stages.' STORY CONTINUES BELOW THIS AD If the Colossal team succeeds in creating a tall bird with huge feet and thick pointed claws resembling the moa, there's also the pressing question of where to put it, said Duke University ecologist Stuart Pimm, who is not involved in the project. 'Can you put a species back into the wild once you've exterminated it there?' he said. 'I think it's exceedingly unlikely that they could do this in any meaningful way.' 'This will be an extremely dangerous animal,' Pimm added. The direction of the project will be shaped by Māori scholars at the University of Canterbury's Ngāi Tahu Research Centre. Ngāi Tahu archaeologist Kyle Davis, an expert in moa bones, said the work has 'really reinvigorated the interest in examining our own traditions and mythology.' At one of the archaeological sites that Jackson and Davis visited to study moa remains, called Pyramid Valley, there are also antique rock art done by Māori people – some depicting moa before their extinction. STORY CONTINUES BELOW THIS AD Paul Scofield, a project adviser and senior curator of natural history at the Canterbury Museum in Christchurch, New Zealand, said he first met the 'Lord of the Rings' director when he went to his house to help him identity which of the nine known species of moa the various bones represented. 'He doesn't just collect some moa bones – he has a comprehensive collection,' said Scofield.

UGC Fellowship, PhD Exam June 2025 Rescheduled, Check Details Here
UGC Fellowship, PhD Exam June 2025 Rescheduled, Check Details Here

NDTV

time9 hours ago

  • NDTV

UGC Fellowship, PhD Exam June 2025 Rescheduled, Check Details Here

CSIR UGC NET June 2025: The National Testing Agency (NTA) has revised the schedule for the Joint CSIR-UGC NET June 2025 exam. In response to multiple representations from candidates citing a clash with the Haryana Teacher Eligibility Test (HTET) 2024, which is scheduled on the same dates, the CSIR UGC NET exam will now be conducted on a single day on July 28. The CSIR UGC NET is a national-level Computer Based Test (CBT) that determines eligibility for the award of Junior Research Fellowship (JRF), appointment as Assistant Professor, and admission to PhD programmes in Indian colleges and universities. As per the revised schedule, the exam on July 28 will cover all five subjects: Mathematical Sciences Earth, Atmospheric, Ocean and Planetary Sciences Chemical Sciences Life Sciences Physical Sciences Candidates will receive their exam city details 8 to 10 days before the examination through an advance city intimation slip. For updates and further details, candidates are advised to regularly check the official NTA websites: and Queries can be addressed to NTA via email at csirnet@ or through the helpline numbers 011-40759000 and 011-69227700.

Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14
Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14

Time of India

time14 hours ago

  • Time of India

Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14

The initial public offering (IPO) of Anthem Biosciences will open for subscription on Monday, July 14. The Bengaluru-based CRDMO player is planning to raise Rs 3,395 crore through the issue. The issue will conclude on Wednesday, July 16. About Anthem Biosciences IPO The IPO is an Offer for Sale (OFS) and comprises stake sale aggregating up to Rs 350 crores each by Ganesh Sambasivam and K Ravindra Chandrappa who are promoter selling shareholders. Up to Rs 1,325 crores will be offloaded by Viridity Tone LLP and up to Rs 320 crores by Portsmouth Technologies LLC (Investor Selling Shareholders). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo It also includes stake sales of Rs 320 crores each by Malay J Barua, Rupesh N Kinekar and Satish Sharma, up to Rs 80 crore by Prakash Kariabettan and up to Rs 10 crore by K Ramakrishnan. About Anthem Biosciences Anthem's business comprises Contract Research, Development and Manufacturing Organization (CRDMO) services and the manufacture and sale of specialty ingredients. It offers a comprehensive, integrated and highly customizable range of CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles. The company claims to have a strong presence across various modalities, such as RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing techniques, such as flow chemistry, enzymatic processes, biocatalysis and fermentation, offering a broad range of technology capabilities for drug development. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Live Events Ajay Bhardwaj (Chairman, MD & CEO), Ganesh Sambasivam (Whole-time Director and Chief Scientific Officer), K Ravindra Chandrappa (Whole-time Director and Chief Operating Officer) and Ishaan Bhardwaj (Vice President) are the Promoters of the company. The company, which was incorporated in 2006, has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL, as of March 31, 2025. According to the RHP, the company is in the process of expanding its custom synthesis capacity at Unit II (Harohalli) by 130 kL as well as expanding its custom synthesis capacity by 25kL and fermentation capacity by 40kL by constructing Unit III (Neoanthem Lifesciences Private Limited, wholly-owned Subsidiary), both expected to be fully operational by the first half of Fiscal 2026. Post-expansion activities, the aggregate annual custom synthesis capacity and fermentation capacity is expected to increase to 425 kL and 182 kL, respectively. The fermentation capacity of 182 kL is expected to be more than six times the capacity of the second largest player in this industry, according to the F&S Report. Anthem Biosciences financials Its revenue from operations increased by 30% to Rs 1,844 crores in FY25 from Rs 1,419 crores in FY24. The PAT for the year ended March 31, 2025 was Rs 451 crores, a jump of 22.86% over FY24. Sai Life Sciences Limited, Syngene International Limited , Cohance Lifesciences Limited , (Formerly Suven Pharmaceuticals) and Divi's Laboratories Limited are the listed peers of Anthem Biosciences, as per its RHP. Anthem Biosciences lead managers The Book Running Lead Managers to the offer are JM Financial Limited , Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited. The equity shares are proposed to be listed on BSE and NSE.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store